GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment Zantac

British drugmaker agrees payment to resolve 80,000 cases alleging cancers were linked to drug known generically as ranitidine

The British drugmaker GSK has struck an agreement to make a payment of up to $2.2bn (£1.7bn) to resolve litigation brought in the US over its heartburn treatment Zantac.

The company said it had struck agreements with 10 plaintiff law firms who represent about 93%, roughly 80,000, of the US state court product liability cases pending against it.